Aethlon Medical Corp (AEMD) - Long-Term Debt to Capital Coefficient

The market dynamics of Aethlon Medical (AEMD) securities demonstrate the 0.00 indicator. Aethlon Medical focuses on developing the Hemopurifier filter for the removal of tumor markers and viruses as it prepares for critical regulatory approvals. While technical development is handled internally, component manufacturing and testing are outsourced to external contractors. Therapy safety is ensured through a streamlined equipment transport mechanism to healthcare facilities.

This indicator measures the proportion of long-term liabilities relative to equity, determining the company's degree of financial leverage. By analyzing the long-term debt-to-equity profile, an investor assesses the sustainability of the financing structure. For Aethlon Medical (AEMD), this metric reflects the cost of supporting the R&D pipeline and Hemopurifier trials. Any trend here signals the methods of resource accumulation prior to regulatory releases. The final value determines the risk of shareholder value dilution.